The effects of diabetes mellitus include long-term damage, dysfunction and failure of various organs

Non-obese type 2 patients, consider the use of metformin or insulin secretagogues

Metformin is the drug of choice in overweight/obese patients. TZDs and acarbose are acceptable alternatives in those who are intolerant to metformin.

If monotherapy fails, a combination of TZDs, acarbose and metformin is recommended. If targets are still not achieved, insulin secretagogues may be added

Combination oral agents is indicated in:

• Combination oral agents is indicated in:

• Newly diagnosed symptomatic patients with HbA1c >10

• Patients who are not reaching targets after 3 months on monotherapy

If targets have not been reached after optimal dose of combination therapy for 3 months, consider adding intermediate-acting/long-acting insulin (BIDS).

• If targets have not been reached after optimal dose of combination therapy for 3 months, consider adding intermediate-acting/long-acting insulin (BIDS).

•